General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Patient assistance programs

Novartis Group companies have established patient assistance programs to help patients in need in both developing and developed countries.

In 2013, Novartis patient assistance programs in the US provided products worth USD 550 million to more than 96,000 patients in need.
Novartis Oncology expanded access to Glivex, Tasigna and Exjade for more than 65,000 patients in 2013.

In the US, for example, through the Novartis Patient Assistance Foundation, Inc., Novartis has designed a number of assistance programs and offers reimbursement hotlines for patients without prescription drug coverage or experiencing financial hardship.

Novartis also supports the Partnership for Prescription Assistance, a single point of access to more than 475 public and private patient assistance programs in the US, including more than 180 programs offered by healthcare companies.

Alcon, our eye care division, helps patients within the US through Alcon Cares, Inc., which provides eye care medication to qualified, low-income individuals at no charge.

First global direct-to-patient access program tackles two rare forms of cancer

Novartis created the first and most far-reaching global direct-to-patient access program with the Glivec International Patient Assistance Programs (GIPAP), which provides treatment for two rare forms of cancer.

Related links:

Read our positions on: